Research Article

Evaluation of Olfactory and Gustatory Function of HIV Infected Women

Ayotunde James Fasunla,¹ Adekunle Daniel,¹ Ukamaka Nwankwo,¹ Kehinde Mobolanle Kuti,² Onyekwere George Nwaorgu,¹ and Olusina Olusegun Akinyinka³

¹Department of Otorhinolaryngology, College of Medicine, University of Ibadan and University College Hospital, Ibadan 200212, Nigeria
²APIN/PEPFAR Clinic, University College Hospital, Ibadan 200212, Nigeria
³Department of Paediatrics, College of Medicine, University of Ibadan and University College Hospital, Ibadan 200212, Nigeria

Correspondence should be addressed to Ayotunde James Fasunla; ayofasunla@gmail.com

Received 3 November 2015; Accepted 15 February 2016

Academic Editor: Glenda Gray

Copyright © 2016 Ayotunde James Fasunla et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Compliance with medication requires good sense of smell and taste. Objective. To evaluate the olfactory and gustatory function of HIV infected women in Ibadan, Nigeria. Methods. A case control study of women comprising 83 HIV infected women and 79 HIV uninfected women. Subjective self-rating of taste and smell function was by visual analogue scale. Olfactory function was measured via olfactory threshold (OT), olfactory discrimination (OD), olfactory identification (OI), and TDI using “Sniffin’ sticks” kits and taste function (Total Taste Strips (TTS) score) measurement was by taste strips. Results. The mean age of the HIV infected women was 43.67 years ± 10.72 and control was 41.48 years ± 10.99. There was no significant difference in the self-reported assessment of smell (p = 0.67) and taste (p = 0.84) of HIV infected and uninfected women. Although the mean OT, OD, OI, TDI, and TTS scores of HIV infected and uninfected women were within the normosmic and normogeusic values, the values were significantly higher in the controls (p < 0.05). Hyposmia was in 39.7% of subjects and 12.6% of controls while hypogeusia was in 15.7% of subjects and 1.3% of controls. Conclusions. Hyposmia and hypogeusia are commoner among the HIV infected women than the HIV uninfected women and the risk increases with an increased duration of highly active antiretroviral therapy.

1. Introduction

Women contribute significantly to socioeconomic growth and development of a society. They also play significant role in home management, family care, and upbringing of children. In most African countries, the culture demands that women prepare safe daily meal for the family and supervise intake of children’s medication when they are ill. They therefore need good sense of smell and taste to prepare savory meal and ensure a safety home environment. However, disease conditions which affect taste and/or smell organs make them not safely perform these roles. The consequences include inability to identify spoilt food or detect smoke in fire or faulty electrical appliances thereby exposing family members to avoidable dangers [1]. They may even add more sugar or salt to food than desired by other members of the family in an attempt to improve the taste thereby making the food taste unpalatable [2–4].

Human immunodeficiency virus (HIV) infection is a public health problem which is more prevalent in the Sub-Saharan Africa region [5, 6]. Women are more infected with HIV than men [7, 8]. HIV infection is a systemic disease which affects virtually every organ-system of the body but with affinity or preference for nervous tissues and immune systems [9–11]. Olfactory nerve endings are located in the olfactory mucosa at the roof of the nasal cavities. Taste buds, which are located in the oral, nasal, and pharyngeal mucosae, are responsible for mediating sweet, sour, salty, and bitter taste. HIV infected individuals are susceptible to opportunistic infections of the upper aerodigestive tract [12, 13] which may affect the function of these taste buds and olfactory nerve endings [14]. The dysfunction of taste...
and smell can impair food intake leading to weight loss. It may also influence compliance with antiretroviral medication thereby contributing to poor therapeutic outcome [14]. These have implications on health and quality of life. Although studies have shown that dysfunction of taste and smell is a side effect of medications [15, 16], it is unclear whether antiretroviral medications affect craving or aversion for a particular type of food taste. The effect of HIV and antiretroviral medication on taste and smell of women has not been investigated in Sub-Saharan Africa. Therefore, this study was designed to evaluate the olfactory and gustatory function of HIV infected women in Ibadan, Nigeria.

2. Patients and Methods

2.1. Study Design. This was a case control study of women at University College Hospital (UCH), Ibadan, between March 2015 and June 2015. The cases were HIV infected women on highly active antiretroviral therapy (HAART) at the President’s Emergency Plan for AIDS Relief (PEPFAR) Clinic, UCH, being supported by AIDS Prevention Initiative Nigeria (APIN). The controls were HIV uninfected women who are students and staff of UCH. The study was approved by the Joint University of Ibadan/University College Hospital, Ibadan (Nigeria) Ethical Review Committee. Informed consent was obtained from the participants in the study.

2.2. Sampling Method. The first ten HIV infected women who gave consent to participate in the study at the PEPFAR clinic on each day of the study were recruited and investigated. Women with history of smoking, rhinorrhea, nasal growth or obstruction, head injury, nasal surgeries, and pregnancy were excluded from the study. All the participants refrained from taking food or drugs orally and exposure to perfume two hours before the commencement of the tests.

2.3. Data Collection Procedures

2.3.1. Structured Questionnaire. A structured questionnaire was used to obtain relevant information on sociodemography, nasal disease, head injury, use of perfume, perception of taste and smell, preference for sweet, salty, sour, and bitter tasting substances, duration of HIV diagnosis, type of HAART, duration of HAART use, and other clinical data from the participants. Social stratification of the participants was based on occupational strata as devised by Famuyiwa et al. [17].

2.3.2. ENT Examination. Ear, nose, and throat examinations of the participants were carried out to exclude the presence of nasal pathologies like nasal discharge, polyps, or tumors and oral/throat thrush, ulcers, or lesions.

2.3.3. Subjective Self-Rating of Smell and Taste Function. All the participants had initial subjective rating of their ability to perceive smell and taste on a visual analogue scale (VAS). The score for each variable ranged from 1 to 10 where 1 represented complete loss of perception of smell or taste and 10 represented excellent perception of smell or taste. A score of 1-2 is very poor, 3-4 is poor, 5-6 is good, 7-8 is very good, and 9-10 is excellent. Thereafter, all the participants in both the test and control groups had both olfacto and taste tests carried out on them.

2.3.4. Virology and Immunology. The participants’ Nadir CD4+ cell count (cells/µL) and viral load (copies/mL) and their most recent CD4+ cell count (cells/µL) and viral load (copies/mL) were retrieved from their clinic records. The protocol at the clinic included determination of the CD4+ cell count and plasma viral loads of HIV infected individual at six-month interval. The CD4+ cell count was determined using the Partec (Munster, Germany) CD4+ easy count based on the principle of no lysing, no wash. For the purpose of this study, HIV infected women were categorized based on the level of their CD4 cell counts (cells/µL) into stage 1 (≥2500 cells/µL), stage 2 (200–499 cells/µL), and stage 3 (<200 cells/µL) in line with Centers for Disease Control and Prevention staging system [18].

2.3.5. Test of Smell. The test of smell comprises odor threshold (OT), odor discrimination (OD), and odor identification (OI). These were performed using pen-like odor dispensing devices called “Sniffin’ sticks.” Individual pen was positioned approximately 2 cm in front of the participants’ nostrils for 3 seconds. Participants were blindfolded during the OD and OT tests to avoid visual identification of the pens.

Odour Identification Testing. The kit for OI test contained sixteen pens already impregnated with sixteen familiar different odours. Each was placed in front of the nostrils of each participant at different times for about 3 seconds and asked to select the source substance that matched the presented odour from four different items in a forced choice procedure (four-alternative forced choice). A period of about 30 seconds was allowed before another pen was presented to prevent adaptation or olfactory desensitization [19, 20]. The number of correctly selected source substances by the participant was recorded. The minimum score that a participant can get is zero and the maximum is 16 [21].

Odour Discrimination Testing. The test for OD contains forty-eight pens which were arranged in sixteen triplets. In each triplet, two of the pens contained the same odour while the third contained another odour. Each pen in a triplet was presented to the nostril of each participant and was expected to identify the pen with a different odour (three-alternative forced choice) [19–21]. They were only allowed to sample each odour once. The triplets were presented at intervals of at least 30 seconds and the individual odour pens at intervals of approximately 3 seconds. When the participant correctly identified the pen with a different odour she was given a point score and when she got it wrong, she had score of zero. The process was repeated for all the 16 triplet pens. The minimum score that a participant can get is zero and the maximum is 16 [21].
2.3.6. Test of Taste. Sixteen filter paper strips (“taste strips,” Burghart, Wedel, Germany) impregnated at one end with 0.05, 0.1, 0.2, or 0.4 g/mL of sucrose (sweet taste); 0.05, 0.09, 0.165, or 0.3 g/mL of citric acid (sour taste); 0.016, 0.04, 0.1, or 0.25 g/mL of sodium chloride (salty taste); or 0.0004, 0.0009, 0.0024, or 0.006 g/mL of quinine hydrochloride (bitter taste) were used to test the gustatory function of the participants [24, 25]. The taste strips were applied on the left and right side of the protruded tongue, 1.5 cm from the tip, at different times resulting in a total of 32 trials.

Before the test of taste was performed, participants were given clean water to rinse their mouth. The taste strips were then presented in increasing concentrations, alternating the side of presentation. The taste strips were presented at intervals of 30 seconds. The participants were told to identify the taste, with their tongue still protruded, from a list of four descriptors, that is, sweet, sour, salty, and bitter (four-alternative forced choice). Wrong identification of each taste strip was given score of 0 and correct identification was given score from 1 to 4. Correct identification of the taste at the lowest concentration was 4 and at the highest one was 1. The minimum and maximum score on one side of the tongue ranged from 0 to 16. Thus, the Total Taste Strip (TTS) score, which is the sum of the score from both sides of the tongue, ranged from 0 to 32. Sweet score < 2, sour score < 2, salty score < 2, bitter score < 1 for each side of the tongue, total score < 9 on each side of the tongue, and TTS < 19 were suggestive of hypoguesia [23].

2.4. Statistical/Data Analysis. The qualitative sociodemographic characteristics of the HIV infected and uninfected women were compared using Chi-square tests. The comparison of mean subjective smell and taste scores between HIV infected and uninfected adults was done using the independent samples t-test. Descriptive data were presented as mean ± standard deviation. Chi-square or Fisher’s exact test was used where appropriate to test the association. Test of associations for categorical variables was done using Chi-square/Fisher’s exact test. Test of association for quantitative variables was done using Student’s t-test and ANOVA. The associations between TDI and TTS of the HIV infected adults and their RNA viral load, CD4 cell count level, and HAART were tested with Pearson correlation. Level of significance was determined at $p < 0.05$, two-tailed level at 95% Confidence Interval (CI), and correlation coefficient ($r$).

3. Results

3.1. Sociodemography. One hundred and sixty-two women participated in the study comprising 83 HIV infected women and 79 HIV uninfected women. The age of the HIV infected women ranged from 20 to 70 years, mean 43.67 years ± 10.72, and that of HIV uninfected women ranged from 20 to 65 years, mean 41.48 years ± 10.99. The mean duration of HIV diagnosis was 80.43 months ± 40.05. All the HIV infected women were on HAART for a mean duration of 69.14 ± 38.92 months. Thirty-eight HIV (45.8%) infected women were on combination therapy with nevirapine, zidovudine, and lamivudine; 35 (42.2%) were on combination of tenofovir, lamivudine, and efavirenz; five (6.0%) were on combination of tenofovir, lamivudine, zidovudine, and atazanavir; and another five (6.0%) women were on combination therapy of tenofovir, lamivudine, lopinavir, and ritonavir. The sociodemographic characteristics of the participants are shown in Table 1.

3.2. Virology and Immunology. The Nadir CD4 cell count of the HIV infected women was from 8 to 527 cells/µL, mean of 186.44 cells/µL ± 117.25, while the most recent CD4 cell count was from 34 to 2892 cells/µL, mean of 548 cells/µL ± 397.79. In addition, the Nadir viral load was from 257 to 1542776 copies/mL, mean of 215385.73 copies/mL ± 309577.61. The most recent viral load level in 57 (68.7%) HIV infected women was undetectable (<200 copies/mL). The remaining 27 HIV infected women had viral load ranging from 244 to 66918 copies/mL, mean of 3002.16 copies/mL ± 10792.93.

3.3. Subjective Self-Rating of Smell and Taste Function of HIV Infected and Uninfected Women. On a visual analogue scale (VAS) from 0 to 10, HIV infected women rated their smell
Table 1: Sociodemographic characteristics of the participants.

| Variable | HIV infected women | HIV uninfected women |
|----------|--------------------|----------------------|
| Age (years) |                    |                      |
| 35 and below | 20 (24.1)          | 56 (70.9)            |
| 36–55 | 51 (61.4)          | 18 (22.8)            |
| 56 and above | 12 (14.5)          | 5 (6.3)              |
| Marital status |                |                      |
| Single | 6 (7.2)           | 31 (39.2)            |
| Married | 64 (77.1)         | 47 (59.5)            |
| Divorced | 3 (3.6)           | 0                    |
| Widow | 10 (12.0)         | 1 (1.3)              |
| Occupation |                 |                      |
| Class 1 | 6 (7.2)           | 12 (15.2)            |
| Class 2 | 26 (31.3)         | 24 (30.4)            |
| Class 3 | 14 (16.9)         | 3 (3.8)              |
| Class 4 | 37 (44.6)         | 32 (40.5)            |
| Class 5 | 0                 | 8 (10.1)             |
| Preference for taste |          |                      |
| Salt | 33 (39.8)       | 29 (36.8)            |
| Sweet | 28 (33.7)        | 34 (43.0)            |
| Sour | 14 (16.9)        | 11 (13.9)            |
| Bitter | 8 (9.6)          | 5 (6.3)              |

function to be from 1 to 10, with mean of 8.8 ± 1.4, and their taste function to be from 2 to 10, with mean of 9.1 ± 1.2. The HIV uninfected women rated their smell function to be from 5 to 10, with mean of 9.1 ± 1.2, and their taste function to be from 2 to 10, with mean of 8.6 ± 1.9. There was no significant difference in the subjective self-rating of smell (p = 0.67) and taste (p = 0.84) between the two groups.

3.4. Objective Assessment of Smell and Taste Function of HIV Infected and Uninfected Women. The mean smell and taste scores of both the HIV infected and uninfected women are shown in Table 2. The mean scores of all the components of both smell and taste tests were greater in the HIV uninfected women than in the HIV infected women. There was a significant difference between mean TDI scores of HIV infected women and HIV uninfected women (p = 0.000). There was also a significant difference in the mean TTS score of HIV infected women and HIV uninfected women (p = 0.040).

Hyposmia is seen in 33 (39.8%) HIV infected women and 10 (12.7%) HIV uninfected women (p = 0.0002) as shown in Table 3. The proportion of participants with hyposmia and the type of olfactory tests is shown in Table 4. Similarly, hypogeusia was seen in 13 (15.7%) HIV infected women and 1 (1.3%) HIV uninfected woman (p = 0.0110; OR = 14.4857 (1.8473–13.5894)) as shown in Table 3. There was a significant correlation between HIV disease stage and hyposmia (r = 0.873; p = 0.000) and hypogeusia (r = 0.851; p = 0.021). In addition, as the stage of HIV disease increases, the proportion of HIV infected women with hyposmia and hypogeusia increases (Table 5). Only 6 (7.2%) HIV infected women have both hyposmia and hypogeusia.

3.5. Comparing Subjective Self-Reporting Assessment with the Objective Assessment of Smell and Taste Function of HIV Infected Women. There was a significant difference between the subjective self-reporting and objective smell (TDI) assessment of the HIV infected women (p = 0.048). However, there was no significant difference between self-reporting and objective taste (TTS) assessment of the HIV infected women (p = 0.064).

The type of HAART regimen and the proportion of HIV infected participants with hyposmia and hypogeusia are shown in Table 6. Two HIV infected women in this study were not on HAART.

Those on HAART have significantly higher odds of hyposmia compared with the controls (p = 0.000; OR = 2.13 (1.597–2.828)). The odds of hyposmia increased with increased duration of HAART usage (Figure 1).

Similarly, those on HAART have significantly higher odds of hypogeusia compared with the controls (p = 0.001; OR = 15.29 (1.950–119.99)). The odds of hypogeusia increased with increased duration of HAART usage (Figure 2).

4. Discussion

The cause of smell and taste dysfunction is multifactorial, even in women. The contribution of HIV infection and antiretroviral medications was investigated in this study using subjective assessment based on visual analogue scale scores and validated objective smell and taste tests. To the best of our knowledge, this is the first study which used these methods to investigate the smell and taste of HIV infected and uninfected women in Sub-Saharan Africa.
Table 2: Comparison of smell and taste of the participants.

| Variable                  | HIV infected women (Mean ± SD) | HIV uninfected women (Mean ± SD) | Level of significance (p value) |
|---------------------------|-------------------------------|---------------------------------|-------------------------------|
| **Smell**                 |                               |                                 |                               |
| Olfactory threshold       | 8.1 ± 5.0                     | 11.4 ± 2.1                      | 0.000                         |
| Olfactory discrimination  | 10.1 ± 5.0                    | 11.7 ± 2.6                      | 0.012                         |
| Olfactory identification  | 9.0 ± 4.7                     | 13.3 ± 3.0                      | 0.000                         |
| TDI                       | 27.3 ± 11.7                   | 36.3 ± 5.0                      | 0.000                         |
| **Taste**                 |                               |                                 |                               |
| Sweet                     | 3.3 ± 0.9                     | 3.8 ± 0.6                       | 0.000                         |
| Sour                      | 3.1 ± 0.9                     | 3.3 ± 0.9                       | 0.034                         |
| Salty                     | 3.1 ± 1.1                     | 3.5 ± 0.8                       | 0.000                         |
| Bitter                    | 3.2 ± 1.0                     | 3.7 ± 0.6                       | 0.000                         |
| TTS                       | 25.3 ± 5.9                    | 29.0 ± 3.8                      | 0.040                         |
| Subjective smell          | 8.8 ± 1.4                     | 9.1 ± 1.2                       | 0.67                          |
| Subjective taste          | 7.6 ± 2.9                     | 8.6 ± 1.9                       | 0.84                          |

Table 3: Participants with hyposmia and hypogeusia.

| Variables                  | TDI | TTS |
|----------------------------|-----|-----|
| **Hyposmia**               | Hyposmia | Normosmia | Hypogeusia | Normogeusia |
| HIV infected women         | n (%) | n (%) | n (%) | n (%) |
| 35 and below               | 8 (9.6) | 12 (14.5) | 4 (4.8) | 16 (19.3) |
| 36–55                      | 19 (22.8) | 32 (38.6) | 6 (7.2) | 45 (54.2) |
| 56 and above               | 6 (7.2) | 6 (7.2) | 3 (3.6) | 9 (10.8) |
| Total                      | 33 (39.8) | 50 (60.2) | 13 (15.7) | 70 (84.3) |
| HIV uninfected women       | n (%) | n (%) | n (%) | n (%) |
| 35 and below               | 5 (6.3) | 51 (64.6) | 0 | 56 (70.9) |
| 36–55                      | 3 (3.8) | 15 (19.0) | 1 (1.3) | 17 (21.5) |
| 56 and above               | 2 (2.5) | 3 (3.8) | 0 | 5 (6.3) |
| Total                      | 10 (12.7) | 69 (87.3) | 1 (1.3) | 78 (98.7) |

Table 4: Types of olfactory dysfunction in the participants.

| Olfactory tests | HIV infected women | HIV uninfected women | Hyposmia n (%) | Odds ratio | 95% CI | Z statistic | P value |
|-----------------|---------------------|-----------------------|----------------|------------|--------|-------------|---------|
| OT              | 27 (81.8)           | 6 (60.0)              | 5.8661         | 2.2671–15.1781 | 3.648  | 0.0003      |
| OD              | 15 (45.5)           | 4 (40.0)              | 4.1360         | 1.3086–13.0722 | 2.418  | 0.0156      |
| OI              | 6 (18.2)            | 2 (20.0)              | 3.0000         | 0.5871–15.3302 | 1.320  | 0.1868      |
| TDI             | 33 (100.0)          | 10 (100.0)            | 4.5540         | 2.0551–10.0913 | 3.734  | 0.0002      |

Table 5: Relationship of HIV infection stage with hyposmia and hypogeusia.

| Stage | Nadir CD4⁺ cell count (cells/μL) | Olfaction of HIV infected women | Gustation of HIV infected women |
|-------|----------------------------------|---------------------------------|---------------------------------|
|       | | Hyposmia | Normosmia | Hypogeusia | Normogeusia | Hyposmia | Normosmia | Hypogeusia | Normogeusia |
| 1     | ≥500  | 8 (9.6%) | 15 (18.1%) | 3 (3.6%) | 7 (8.4%) |
| 2     | 200–499 | 11 (13.2%) | 16 (19.3%) | 5 (6.0%) | 27 (32.5%) |
| 3     | <200  | 14 (16.9%) | 19 (22.9%) | 5 (6.0%) | 36 (43.4%) |
|       | 33 (39.7) | 50 (60.3) | 13 (15.7) | 70 (84.3) |

AIDS Research and Treatment
Table 6: Relationship of highly active antiretroviral therapy with hyposmia and hypogeusia.

| Highly active antiretroviral therapy (HAART) | Olfaction test (TDI) | Gustation test (TTS) |
|---------------------------------------------|----------------------|---------------------|
|                                             | Hyposmia | Normosmia | Hypogeusia | Normogeusia |
| Nevirapine, zidovudine, and lamivudine       | 16       | 20        | 7         | 29         |
| Tenofovir, lamivudine, and efavirenz          | 13       | 22        | 5         | 30         |
| Tenofovir, lamivudine, zidovudine, and atazanavir | 1        | 4         | 1         | 4          |
| Tenofovir, lamivudine, lopinavir, and ritonavir | 2        | 3         | 0         | 5          |

Little attention is given to investigating smell and taste function in HIV infected women. Most people with smell dysfunction may not recognize it as evidenced by the significant difference between the subjective self-reporting and objective olfactory assessment of the women in this study. Although none of the participants in this study had anosmia, there was a trend towards more hyposmia/anosmia among HIV infected women than in the HIV uninfected women (Table 4). The prevalence of hyposmia was higher in HIV infected women (39.8%) than in HIV uninfected women (12.6%). The higher prevalence of hyposmia in the HIV infected women may be due to inflammatory changes which occurred in the olfactory mucosa from readily encountered opportunistic infection of the upper respiratory tract and the neurotropic effect of HIV on the olfactory nerve [10, 12, 13]. Chronic inflammation, which is a common disease among the HIV infected individuals, has been implicated in the aetiology of hyposmia [13]. Although none of the participants had rhinosinusitis at the time of investigation, the repeated inflammation of the olfactory mucosa from recurrent rhinosinusitis over a long period of time can damage the olfactory epithelium with resultant smell dysfunction. The improved immunity of the HIV infected women as evidenced by a higher level of mean latest CD4 cell count compared to the Nadir CD4 cell count would have reduced the possibility of opportunistic rhinosinusitis in them.

The prevalence of hypogeusia in HIV infected women (15.7%) was higher than in healthy HIV uninfected women (1.3%). Most people with taste dysfunction may notice and report it as evidenced by the nonsignificant difference between the subjective and objective taste assessment of the women in this study. HIV infection predisposes people to oral candidiasis and lesions which may cause taste dysfunction [12]. Dryness of the oral cavity from inadequate fluid intake and inflammation of salivary glands can also contribute to gustatory dysfunction by reducing transportation of taste chemicals to taste buds. Although whole mouth taste dysfunction is rare, taste sensitivity is directly related to the number of taste papillae and taste buds that are stimulated [26, 27]. Ageing process and viral infections like HIV can reduce the quantity of taste buds and papillae in the upper orodigestive tract [28, 29]. These chemosensory abnormalities can impair food intake thereby contributing to significant weight loss [14]. HIV associated wasting is an increasingly common clinical manifestation of AIDS. Although rarely appreciated, taste dysfunction can alter choice of food and pattern of its consumption thereby predisposing to weight loss or gain, hypertension (because of frequent consumption of salt in bigger quantity to improve food taste), and diabetes (because of frequent sugar consumption to improve food taste) and, in some cases, may impair immunity and even cause death. The increased preferences for salty and sweet tasting substances in 39.8% and 33.7% of HIV infected women (Table 1) will encourage consumption of more than needed salt (electrolytes) and sugar. In individuals who are at risk of developing hypertension, excess salt intake will cause expansion of body fluid volume resulting in hypertension. In addition, excess sugar consumption may increase the risk of excessive weight gain or diabetes in those who are prone to it [30, 31]. The comorbid diseases of hypertension and diabetes in HIV infected women will definitely impair their quality of life and standard of living.

Women require optimal nutrient intake for maintenance of their body function, menstruation, and proper growth and development of pregnancy. HIV infected women require good nutrition for improved immunologic status to fight against opportunistic infections. Poor nutrition may worsen HIV disease progression, depress immune system with resultant frequent opportunistic infections, and impair optimal...
response to antiretroviral medication. The perceptions of taste and smell play important roles in stimulating caloric intake and optimising nutrient absorption through cephalic phase reflexes [2–4]. In instances where nutrient intake is inadequate and chemosensory perception is considered a likely contributor to taste and smell losses, the use of supplements and flavor enhancers like monosodium glutamate may improve both quality and quantity of intake [3, 32].

Reports have shown that OT can reflect more on the function of the peripheral olfactory system (perception of odour) while tests of OI and OD reflect more on the cognitive performance (recognition and memory of specific odour) [33, 34]. Majority of HIV infected and uninfected women with hyposmia will have problem with odour perception while lesser proportion will have difficulty in recognizing or keeping the memory of the specific odour. These significant taste and smell losses in HIV infected women may be of clinical significance in the development or progression of HIV associated wasting [35]. It is therefore important to make them aware of this problem and warn them of the associated risk. A significant correlation was established between Centers for Disease Control and Prevention stage of HIV infection and smell and taste function. CD4-receptors containing cells are the portal of entry of HIV, and the rate of CD4 cell destruction is directly proportional to progressive replication of HIV and susceptibility to opportunistic infections. Administration of HAART will improve the CD4 cell counts level, lower HIV disease stage, and then improve the hyposmia and quality of life. Losses of smell and taste have been reported to be rare side effects of some classes of medication [15, 16, 36]. The effects of HAART on smell and taste function of HIV infected individuals have been documented [37–39]. In this study, the HIV infected women on HAART are 2.13 and 15.29 times more likely to develop hyposmia and hypogeusia, respectively, than the controls. It would have been good to see this relationship between HIV infected women on HAART and those not on HAART. The analysis could not be done because only two HIV infected women in this study were not on HAART. This needs to be investigated in the future. This present study also showed that the longer the use of HAART, the higher the odds of hyposmia and hypogeusia. The long mean duration of HAART use by HIV infected women might have contributed to the observed increase in the mean CD4 cell count and decrease in mean RNA viral load which are indicators of treatment outcome and prognosis. It is also a long enough time for dysfunctioning taste buds and papillae to have regenerated thereby contributing to the observed low proportion of subjects with hyposmia in this study.

5. Conclusions

Hyposmia and hypogeusia are commoner among the HIV infected women than the HIV uninfected women and the risk increases with an increased duration of highly active antiretroviral therapy.

Disclaimer

The contents are solely the responsibility of the authors and do not represent the official views of the funding institutions.

Conflict of Interests

The authors declare no conflict of interests.

Acknowledgments

The authors appreciate all the patients and staff of President's Emergency Plan for AIDS Relief (PEPFAR) and AIDS Prevention Initiative Nigeria (APIN) Clinic at the University College Hospital, Ibadan, Nigeria, for their support during data collection. This work was funded in part by the US Department of Health and Human Services, Health Resources and Services Administration (U51HA02522), and the Centers for Disease Control and Prevention (CDC) through a cooperative agreement with APIN (PS 001058). In addition, support was provided by the Fogarty International Center (NIH) R24TW008878, Medical Education Partnership in Nigeria.

References

[1] D. V. Santos, E. R. Reiter, L. J. DiNardo, and R. M. Costanzo, “Hazardous events associated with impaired olfactory function,” Archives of Otolaryngology—Head and Neck Surgery, vol. 130, no. 3, pp. 317–319, 2004.
[2] K. Aschenbrenner, C. Hummel, K. Teshner et al., “The influence of olfactory loss on dietary behaviors,” Laryngoscope, vol. 118, no. 1, pp. 135–144, 2008.
[3] M.-F. A. M. Mathey, E. Siebelink, C. de Graaf, and W. A. Van Staveren, “Flavor enhancement of food improves dietary intake and nutritional status of elderly nursing home residents,” Journals of Gerontology: Series A—Biological Sciences and Medical Sciences, vol. 56, no. 4, pp. M200–M205, 2001.
[4] V. B. Duffy, J. R. Backstrand, and A. M. Ferris, “Olfactory dysfunction and related nutritional risk in free-living, elderly women,” Journal of the American Dietetic Association, vol. 95, no. 8, pp. 879–884, 1995.
[5] P. Razavi, K. Hajifhalalain, B. Saeidi et al., “Quality of life among persons with HIV/AIDS in Iran: internal reliability and validity of an international instrument and associated factors,” AIDS Research and Treatment, vol. 2012, Article ID 849406, 6 pages, 2012.
[6] V. Hernando, D. Alvarez-del Arco, B. Alejos et al., “HIV infection in migrant populations in the European Union and European Economic Area in 2007–2012: an epidemic on the move,” Journal of Acquired Immune Deficiency Syndromes, vol. 70, no. 2, pp. 204–211, 2015.
[7] L. Johnston, H. Oumzil, H. El Rhilani, A. Latifi, A. Bennani, and K. Alami, Sex Differences in HIV Prevalence, Behavioral Risks and Prevention Needs among Anglophone and Francophone Sub-Saharan African Migrants Living in Rabat, AIDS and Behavior, Rabat, Morocco, 2015.
[8] R. Jewkes, Y. Sikweyiya, R. Morrell, and K. Dunkle, “The relationship between intimate partner violence, rape and HIV amongst South African men: a cross-sectional study,” PLoS ONE, vol. 6, no. 9, Article ID e24256, 2011.
9. M. A. Pagano, P. E. Cahn, M. L. Garau et al., “Brain-stem auditory evoked potentials in human immunodeficiency virus-seropositive patients with and without acquired immunodeficiency syndrome,” *Archives of Neurology*, vol. 49, no. 2, pp. 166–169, 1992.

10. R. L. Doty and C. P. Kimmelman, “Smell and taste and their disorders,” in *Diseases of the Nervous System*, A. K. Asbury, G. M. McKhann, and W. I. McDonald, Eds., vol. 1, pp. 466–478, W.B. Saunders Company, Philadelphia, Pa, USA, 1986.

11. W. E. Karnes, “Diseases of the seventh cranial nerve,” in *Peripheral Neuropathy*, P. J. Dyck, P. K. Thomas, E. H. Lambert, and R. Bunge, Eds., vol. 2, pp. 1266–1299, W.B. Saunders, Philadelphia, Pa, USA, 2nd edition, 1984.

12. A. Berberi, Z. Noujeim, and G. Aoun, “Epidemiology of oropharyngeal candidiasis in human immunodeficiency virus/acquired immune deficiency syndrome patients and CD4+ counts,” *Journal of International Oral Health*, vol. 7, no. 3, pp. 20–23, 2015.

13. A. R. Shah, J. A. Hairston, and T. A. Tami, “Sinusitis in HIV: microbiology and therapy,” *Current Infectious Disease Reports*, vol. 7, no. 3, pp. 165–169, 2005.

14. A. E. Heald and S. S. Schiffman, “Taste and smell. Neglected senses that contribute to the malnutrition of AIDS,” *North Carolina Medical Journal*, vol. 58, no. 2, pp. 100–104, 1997.

15. R. L. Doty and S. M. Bromley, “Effects of drugs on olfaction and taste,” *Otolaryngologic Clinics of North America*, vol. 37, no. 6, pp. 1229–1254, 2004.

16. J. M. Norés, B. Biacabe, and P. Bonfils, “Olfactory disorders due to medicinal drugs: an analysis and review of the literature,” *Revue de Medecine Interne*, vol. 21, no. II, pp. 972–977, 2000.

17. O. O. Famuyiwa, D. A. Olorunshola, and A. Derin, “Some family factors in sickle cell anaemia in Lagos, Nigeria,” *Nigerian Medical Practitioner*, vol. 35, pp. 70–73, 1998.

18. HIV Classification: CDC and WHO staging systems, July 2015, http://www.aidsnet.org/guide/hiv-classification-cdc-and-who-staging-systems.

19. T. Hummel, B. Sekinger, S. R. Wolf, E. Pauli, and G. Kobal, “‘Sniffin’ sticks’: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold,” *Chemical Senses*, vol. 22, no. 1, pp. 39–52, 1997.

20. T. Hummel, G. Kobal, H. Gudziol, and A. Mackay-Sim, “Normative data for the ‘Sniffin’ Sticks’ including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects,” *European Archives of Oto-Rhino-Laryngology*, vol. 264, no. 3, pp. 237–243, 2007.

21. S. Nordin, D. A. Broman, J. K. Olofsson, and M. Wulf, “A longitudinal descriptive study of self-reported abnormal smell and taste perception in pregnant women,” *Chemical Senses*, vol. 29, no. 5, pp. 391–402, 2004.

22. Burghart Messtechnik GmbH, *Sniffin Sticks Instruction for Use*, Burghart Messtechnik GmbH, Wedel, Germany, 2014.

23. G. Kobal, T. Hummel, B. Sekinger, S. Barz, S. Roscher, and S. Wolf, “‘Sniffin sticks’: screening of olfactory performance,” *Rhinology*, vol. 34, no. 4, pp. 222–226, 1996.

24. B. N. Landis, A. Welge-Luessen, A. Bramerson et al., “‘Taste Strips’—a rapid lateralized, gustatory bedside identification test based on impregnated filter papers,” *Journal of Neurology*, vol. 256, no. 2, pp. 242–248, 2009.

25. C. Mueller, S. Kallert, B. Renner et al., “Quantitative assessment of gustatory function in a clinical context using impregnated ‘taste strips’,” *Rhinology*, vol. 41, no. 1, pp. 2–6, 2003.

26. R. L. Doty, R. Bagla, M. Morgenson, and N. Mirza, “NaCl thresholds: relationship to anterior tongue locus, area of stimulation, and number of fungiform papillae,” *Psychology and Behavior*, vol. 72, no. 3, pp. 373–378, 2001.

27. S. L. Miller, N. Mirza, and R. L. Doty, “Electrogustometric thresholds: relationship to anterior tongue locus, area of stimulation, and number of fungiform papillae,” *Psychology and Behavior*, vol. 75, no. 5, pp. 753–757, 2002.

28. T. Matsuda and R. L. Doty, “Regional taste sensitivity to NaCl: relationship to subject age, tongue locus and area of stimulation,” *Chemical Senses*, vol. 20, no. 3, pp. 283–290, 1995.

29. D. A. Deems, D. M. Yen, A. Kreshak, and R. L. Doty, “Spon-aneous resolution of dysgeusia,” *Archives of Otolaryngology—Head and Neck Surgery*, vol. 122, no. 9, pp. 961–963, 1996.

30. D. J. Bowen, “Taste and food preference changes across the course of pregnancy,” *Appetite*, vol. 19, no. 3, pp. 233–242, 1992.

31. V. B. Duffy, L. M. Bartoshuk, R. Striegel-Moore, and J. Rodin, “Taste changes across pregnancy,” *Annals of the New York Academy of Sciences*, vol. 855, pp. 805–809, 1998.

32. S. Rodas-Moya, S. Kodish, M. Manary, N. Grede, and S. de Pee, “Preferences for food and nutritional supplements among adult people living with HIV in Malawi,” *Public Health Nutrition*, vol. 19, no. 4, pp. 693–702, 2016.

33. M. Jones-Gotman and R. J. Zatorre, “Olfactory identification deficits in patients with focal cerebral excision,” *Neuropsychologia*, vol. 26, no. 3, pp. 387–400, 1988.

34. P. J. Moberg, R. Agrin, R. E. Gur, R. C. Gur, B. I. Turetsky, and R. L. Doty, “Olfactory dysfunction in schizophrenia: a qualitative and quantitative review,” *Neuropsychopharmacology*, vol. 21, no. 3, pp. 325–340, 1999.

35. C. S. Graham, B. G. Graham, J. A. Bartlett, A. E. Heald, and S. S. Schiffman, “Taste and smell losses in HIV infected patients,” *Physiology and Behavior*, vol. 58, no. 2, pp. 287–293, 1995.

36. R. I. Henkin, “Drug-induced taste and smell disorders. Inci-dence, mechanisms and management related primarily to treat-ment of sensory receptor dysfunction,” *Drug Safety*, vol. 11, no. 5, pp. 318–377, 1994.

37. E. Gir, C. G. Vaichulonis, and M. D. de Oliveira, “Adhesion to anti-retroviral therapy by individuals with HIV/AIDS seen at an institution in the interior of São Paulo,” *Revista Latino-Americana de Enfermagem*, vol. 13, no. 5, pp. 634–641, 2005.

38. J. V. Raja, P. Rai, M. Khan, A. Banu, and S. Bhuthaiah, “Evaluation of gustatory function in HIV-infected subjects and without HAART,” *Journal of Oral Pathology and Medicine*, vol. 42, no. 3, pp. 216–221, 2013.

39. M. O. Johnson, T. Stallworth, and T. B. Neilands, “The drugs or the disease? Causal attributions of symptoms held by HIV-positive adults on HAART,” *AIDS and Behavior*, vol. 7, no. 2, pp. 109–117, 2003.